UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Doxorubicin-Loaded PLGA Nanoparticles for Cancer Therapy: Molecular Weight Effect of PLGA in Doxorubicin Release for Controlling Immunogenic Cell Death

Pharmaceutics, 2020-11, Vol.12 (12), p.1165

2020

Volltextzugriff (PDF)

All-in-one glycol chitosan nanoparticles for co-delivery of doxorubicin and anti-PD-L1 peptide in cancer immunotherapy

Bioactive materials, 2023-10, Vol.28, p.358-375

2023

Volltextzugriff (PDF)

Preclinical development of carrier-free prodrug nanoparticles for enhanced antitumor therapeutic potential with less toxicity

Journal of nanobiotechnology, 2022-10, Vol.20 (1), p.1-436, Article 436

2022

Volltextzugriff (PDF)

Cathepsin B-Overexpressed Tumor Cell Activatable Albumin-Binding Doxorubicin Prodrug for Cancer-Targeted Therapy

Pharmaceutics, 2021-12, Vol.14 (1), p.83

2021

Volltextzugriff (PDF)

Sustained and Long-Term Release of Doxorubicin from PLGA Nanoparticles for Eliciting Anti-Tumor Immune Responses

Pharmaceutics, 2022-02, Vol.14 (3), p.474

2022

Volltextzugriff (PDF)

Photo-induced crosslinked and anti-PD-L1 peptide incorporated liposomes to promote PD-L1 multivalent binding for effective immune checkpoint blockade therapy

Acta pharmaceutica Sinica. B, 2024-03, Vol.14 (3), p.1428-1440

2024

Volltextzugriff (PDF)

Implantable micro-scale LED device guided photodynamic therapy to potentiate antitumor immunity with mild visible light

Biomaterials research, 2022-10, Vol.26 (1), p.1-56

2022

Volltextzugriff (PDF)

Mesenchymal Stem Cell-Mediated Deep Tumor Delivery of Gold Nanorod for Photothermal Therapy

Nanomaterials (Basel, Switzerland), 2022-09, Vol.12 (19), p.3410

2022

Volltextzugriff (PDF)

Tumor-activated carrier-free prodrug nanoparticles for targeted cancer Immunotherapy: Preclinical evidence for safe and effective drug delivery

Advanced drug delivery reviews, 2022-04, Vol.183, p.114177-114177, Article 114177

2022

Volltextzugriff (PDF)

Visible-Light-Triggered Prodrug Nanoparticles Combine Chemotherapy and Photodynamic Therapy to Potentiate Checkpoint Blockade Cancer Immunotherapy

ACS nano, 2021-07, Vol.15 (7), p.12086-12098

2021

Volltextzugriff (PDF)

Cathepsin B-responsive prodrugs for cancer-targeted therapy: Recent advances and progress for clinical translation

Nano research, 2022-08, Vol.15 (8), p.7247-7266

2022

Volltextzugriff (PDF)

Combination of cancer-specific prodrug nanoparticle with Bcl-2 inhibitor to overcome acquired drug resistance

Journal of controlled release, 2021-02, Vol.330, p.920-932

2021

Volltextzugriff (PDF)

Cancer-specific drug-drug nanoparticles of pro-apoptotic and cathepsin B-cleavable peptide-conjugated doxorubicin for drug-resistant cancer therapy

Biomaterials, 2020-12, Vol.261, p.120347-120347, Article 120347

2020

Volltextzugriff (PDF)

Necroptosis‐Inducible Polymeric Nanobubbles for Enhanced Cancer Sonoimmunotherapy

Advanced materials (Weinheim), 2020-04, Vol.32 (16), p.e1907953-n/a

2020

Volltextzugriff (PDF)

Cancer-activated doxorubicin prodrug nanoparticles induce preferential immune response with minimal doxorubicin-related toxicity

Biomaterials, 2021-05, Vol.272, p.120791-120791, Article 120791

2021

Volltextzugriff (PDF)

Liposome-mediated PD-L1 multivalent binding promotes the lysosomal degradation of PD-L1 for T cell-mediated antitumor immunity

Biomaterials, 2022-11, Vol.290, p.121841-121841, Article 121841

2022

Volltextzugriff (PDF)

In Situ One-Step Fluorescence Labeling Strategy of Exosomes via Bioorthogonal Click Chemistry for Real-Time Exosome Tracking In Vitro and In Vivo

Bioconjugate chemistry, 2020-05, Vol.31 (5), p.1562-1574

2020

Volltextzugriff (PDF)

Anti-PD-L1 peptide-conjugated prodrug nanoparticles for targeted cancer immunotherapy combining PD-L1 blockade with immunogenic cell death

Theranostics, 2022-01, Vol.12 (5), p.1999-2014

2022

Volltextzugriff (PDF)

Comparative study of cathepsin B-cleavable linkers for the optimal design of cathepsin B-specific doxorubicin prodrug nanoparticles for targeted cancer therapy

Biomaterials, 2022-10, Vol.289, p.121806-121806, Article 121806

2022

Volltextzugriff (PDF)

Epidermal growth factor (EGF)-based activatable probe for predicting therapeutic outcome of an EGF-based doxorubicin prodrug

Journal of controlled release, 2020-12, Vol.328, p.222-236

2020

Volltextzugriff (PDF)

Rediscovery of nanoparticle-based therapeutics: boosting immunogenic cell death for potential application in cancer immunotherapy

Journal of materials chemistry. B, Materials for biology and medicine, 2021-05, Vol.9 (19), p.3983-41

2021

Volltextzugriff (PDF)

Predicting in vivo therapeutic efficacy of bioorthogonally labeled endothelial progenitor cells in hind limb ischemia models via non-invasive fluorescence molecular tomography

Biomaterials, 2021-01, Vol.266, p.120472, Article 120472

2021

Volltextzugriff (PDF)

Cancer Immunotherapy: Necroptosis‐Inducible Polymeric Nanobubbles for Enhanced Cancer Sonoimmunotherapy (Adv. Mater. 16/2020)

Advanced materials (Weinheim), 2020-04, Vol.32 (16), p.n/a

2020

Volltextzugriff (PDF)

SARS-CoV-2 in Malaysia: A surge of reinfection during the predominantly Omicron period

The Lancet regional health. Western Pacific, 2022-09, Vol.26, p.100572-100572, Article 100572

2022

Volltextzugriff (PDF)

Long short-term memory artificial neural network model for prediction of prostate cancer survival outcomes according to initial treatment strategy: development of an online decision-making support system

World journal of urology, 2020-10, Vol.38 (10), p.2469-2476

2020

Volltextzugriff (PDF)

1 – 25 von 28

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(27)
Mit Volltextzugriff
(27)

Publikationsform

Artikel
(27)
Buchkapitel
(1)

Sprache

Englisch
(28)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Doxorubicin-Loaded PLGA Nanoparticles for Cancer Therapy: Molecular Weight Effect of PLGA in Doxorubicin Release for Controlling Immunogenic Cell Death

All-in-one glycol chitosan nanoparticles for co-delivery of doxorubicin and anti-PD-L1 peptide in cancer immunotherapy

Preclinical development of carrier-free prodrug nanoparticles for enhanced antitumor therapeutic potential with less toxicity

Cathepsin B-Overexpressed Tumor Cell Activatable Albumin-Binding Doxorubicin Prodrug for Cancer-Targeted Therapy

Sustained and Long-Term Release of Doxorubicin from PLGA Nanoparticles for Eliciting Anti-Tumor Immune Responses

Photo-induced crosslinked and anti-PD-L1 peptide incorporated liposomes to promote PD-L1 multivalent binding for effective immune checkpoint blockade therapy

Implantable micro-scale LED device guided photodynamic therapy to potentiate antitumor immunity with mild visible light

Mesenchymal Stem Cell-Mediated Deep Tumor Delivery of Gold Nanorod for Photothermal Therapy

Tumor-activated carrier-free prodrug nanoparticles for targeted cancer Immunotherapy: Preclinical evidence for safe and effective drug delivery

Visible-Light-Triggered Prodrug Nanoparticles Combine Chemotherapy and Photodynamic Therapy to Potentiate Checkpoint Blockade Cancer Immunotherapy

Cathepsin B-responsive prodrugs for cancer-targeted therapy: Recent advances and progress for clinical translation

Combination of cancer-specific prodrug nanoparticle with Bcl-2 inhibitor to overcome acquired drug resistance

Cancer-specific drug-drug nanoparticles of pro-apoptotic and cathepsin B-cleavable peptide-conjugated doxorubicin for drug-resistant cancer therapy

Necroptosis‐Inducible Polymeric Nanobubbles for Enhanced Cancer Sonoimmunotherapy

Cancer-activated doxorubicin prodrug nanoparticles induce preferential immune response with minimal doxorubicin-related toxicity

Liposome-mediated PD-L1 multivalent binding promotes the lysosomal degradation of PD-L1 for T cell-mediated antitumor immunity

In Situ One-Step Fluorescence Labeling Strategy of Exosomes via Bioorthogonal Click Chemistry for Real-Time Exosome Tracking In Vitro and In Vivo

Anti-PD-L1 peptide-conjugated prodrug nanoparticles for targeted cancer immunotherapy combining PD-L1 blockade with immunogenic cell death

Comparative study of cathepsin B-cleavable linkers for the optimal design of cathepsin B-specific doxorubicin prodrug nanoparticles for targeted cancer therapy

Epidermal growth factor (EGF)-based activatable probe for predicting therapeutic outcome of an EGF-based doxorubicin prodrug

Rediscovery of nanoparticle-based therapeutics: boosting immunogenic cell death for potential application in cancer immunotherapy

Predicting in vivo therapeutic efficacy of bioorthogonally labeled endothelial progenitor cells in hind limb ischemia models via non-invasive fluorescence molecular tomography

Cancer Immunotherapy: Necroptosis‐Inducible Polymeric Nanobubbles for Enhanced Cancer Sonoimmunotherapy (Adv. Mater. 16/2020)

SARS-CoV-2 in Malaysia: A surge of reinfection during the predominantly Omicron period

Long short-term memory artificial neural network model for prediction of prostate cancer survival outcomes according to initial treatment strategy: development of an online decision-making support system

Suchergebnisse filtern